Visual Abstract

The Control-IQ technology Observational (CLIO) study prospectively follows a large, diverse cohort with type 1 diabetes with varied insulin use and baseline glycemic control. To study insulin use on the t:slim X2 pump with Control-IQ technology, we compared insulin delivery during the study to standard formulas for predicting correction factor (CF = 1,800/total daily dose) and carbohydrate ratio (CR = 450/total daily dose).

Basal/bolus ratios, CF prediction factor (CF-PF = total daily dose * CF) and CR prediction factor (CR-PF = total daily dose * CR) were analyzed in 1,499 participants who uploaded at least 21 days of pump data to Tandem’s t:connect® web application and had ≥75% CGM use during this time. Data were compared by age group with the Kruskal-Wallis H-test.

Percent basal insulin delivered (including automated increases and decreases in basal delivery) was lower in younger children (40.3%) vs. adults (45-53%, p<0.001). CF-PF was significantly greater in children and teenagers, with the highest CF-PF of 2,380 in the 14-18-year age group, then gradually decreasing to 1,647. CR-PF was lowest in children age 6-9 and in adults age ≥65, at 360 and 387, respectively (Table 1).

Insulin use with the t:slim X2 pump with Control-IQ technology differed from standard prediction formulas across age groups in this study cohort. Examining insulin use patterns when adjusting pump settings may assist with optimizing outcomes.

graphic
View largeDownload slide
Disclosure

J. E. Pinsker: Advisory Panel; Self; Medtronic, Consultant; Self; Eli Lilly and Company, Tandem Diabetes Care, Research Support; Self; Dexcom, Inc., Insulet Corporation, Medtronic, Tandem Diabetes Care. H. Singh: Employee; Self; Tandem Diabetes Care. A. Constantin: Employee; Self; Tandem Diabetes Care. B. Dokken: Employee; Self; Tandem Diabetes Care, Stock/Shareholder; Self; Tandem Diabetes Care. K. N. White: Employee; Self; Tandem Diabetes Care. M. Mcelwee-malloy: Employee; Self; Tandem Diabetes Care. L. Mueller: Research Support; Self; Dexcom, Inc., Tandem Diabetes Care. S. Habif: Employee; Self; Tandem Diabetes Care.

Funding

Tandem Diabetes Care

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.